Clinical Trial Update: Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 clinical trial of ranibizumab for choroidal neovascularization associated with angioid streaks has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioid Streaks
• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Angioid Streaks | Phase 1, Phase 2 | Status: WITHDRAWN